Abstract:1045 Objectives: The overall aim of this study was to validate I-131-PD-L1 SPECT tumor imaging and therapy, especially patients who has poor response to anti PD-L1 mAb therapy based on successful preparation of the probe with excellent stability. Methods: Anti-PD-L1(experimental probe) and IgG (control) were radiolabeled with iodine-131 (I-131-PD-L1, I-131-IgG) and were characterized in vitro, respectively. The stability of the probe and 4T1 cell up-taking after preparation of I-131-PD-L1 was prepared. Ability ofI-131-PD-L1 targeting to tumor was verified by bioditribution and SPECT, including blockade, I-131-IgG and I-131-PD-L1 (human). Expression of PD-L1 in tumor was tested by immunohistochemistry (IHC). To verify their therapeutic value, the study was recorded volume of tumor and their death in groups:I-131-PD-L1+ PD-L1 mAb, I-131-PD-L1, PD-L1 mAb and NS control. The side effects by I-131-PD-L1 and PD-L1 mAb were observed. Results: I-131-PD-L1 was successfully prepared and collected into EP tubes after purification by PD10 Column, with radiochemical yield (RCY): 80.21%±2.98% (n=5) and radiochemical purity (RCP): 96.51%±1.10% (n=5). The probe kept excellent stability with RCP>92% at 72 hours in vitro (n=6), RCP>90% in vivo at 24 hours and RCP>80% in vivo at 72 hours (n=3). The up-taking ratio peaked at 2 hours with 3.18%±0.86% (n=6). Ratio of T/M and T/B reached at 8.66±1.46 and 6.31±1.95 in biodistribution at 120 hours and I-131-PD-L1 in tumor was significantly suppressed (F=17.279, P=0.006) in blockade biodistribution. The breast tumor could be imaged by SPECT at 24 hours and the tumor gradually showed clearer at 48 hours and 72 hours post-injection and never be imaged in I-131-IgG (mouse), I-131-PD-L1 (blockade) and I-131-PD-L1 (human) at 72 hours. I-131-PD-L1+mAb could significantly suppress tumor growth than others groups; the median survivals of I-131-PD-L1+mAb was greatly longer than other groups, and the last one in combined therapy group survived till the 41st day which was better than mice in other groups. In the second PD-L1 mAb therapy (10 μg/g) which performed at 96 hours after the first mAb therapy (10 μg/g), we observed that 9/12 mice displayed serious adverse drug reaction of respiratory system, and died in 12 hours. Hepatorenal functions would keep normal at 7.4 MBq (200 μCi), but weight of mice dramatically descended due to poor appetite. Conclusions: I-131-PD-L1 could noninvasively monitor the expression of PD-L1 in breast tumor by SPECT scan. The probes could dramatically suppress tumor and prolong survival time. Key Words: SPECT; PD-L; Iodine-131; Theranostic probe; Molecular imaging

In Vivo Distribution and Therapeutic Efficacy of Radioiodine-Labeled pH-Low Insertion Peptide Variant 3 in a Mouse Model of Breast Cancer

Comparative Study of Tumor Targeting and Biodistribution of pH (Low) Insertion Peptides (pHLIP® Peptides) Conjugated with Different Fluorescent Dyes

Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple-Negative Breast Cancer Using Radiolabeled Anti-Programmed Death-Ligand 1 Monoclonal Antibody

Evaluation of the therapeutic efficacy of sequential therapy involving percutaneous microwave ablation in combination with 131I-hypericin using the VX2 rabbit breast solid tumor model

Experimental Study on Radioiodine Labeled Anti-PD-L1 Monoclonal Tibody As Novel Tumor Immunosuppressive Agent Imaging Probe

The Further Study on Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovascularization As Well As Tumor Cells in Molecular Tumor Imaging

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD-L1 Expression In Vivo

Enhanced Tumor Inhibiting Effect of 131I-Bdi-1-based Radioimmunotherapy and Cytosine Deaminase Gene Therapy Modulated by a Radio-Sensitive Promoter in Nude Mice Bearing Bladder Cancer

Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice

Intratumoral Expression of Mature Human Neutrophil Peptide-1 Potentiates the Therapeutic Effect of Doxorubicin in a Mouse 4T1 Breast Cancer Model

Suppression of Breast Tumor Growth by DNA Vaccination Against Phosphatase of Regenerating Liver 3

Recombinant Peptide HVGGSSV Targeting to Irradiated Human Pancreatic Carcinoma in Nude Mice

In Situ Insonation of Alkaline Buffer Containing Liposomes Leads to a Net Improvement of the Therapeutic Outcome in a Triple Negative Breast Cancer Murine Model.

Radioiodination, Purification, and Evaluation of Antihuman Tumor-Derived Immunoglobulin G Light Chain Monoclonal Antibody in Tumor-Bearing Nude Mice.

The Combined Therapeutic Effects of 131Iodine-Labeled Multifunctional Copper Sulfide-Loaded Microspheres in Treating Breast Cancer.

Assessment of bioactive peptides derived from laminin-111 as prospective breast cancer-targeting agents

Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA.

Regulation of Ion Homeostasis for Enhanced Tumor Radio‐Immunotherapy

Aiming the magic bullet: targeted delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides

Experimental study on effects of intratumoral injection of paclitaxel-loaded poly (lactic-co-glycolic acid) micro-spheres on Hep-2 laryngeal squamous cell carcinoma xenografts in nude mice